Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Web Exclusives

Web Exclusives published on December 11, 2018 in Supportive Care
Bone metastases are exceedingly common among patients with cancer and can significantly affect quality of life. Approximately 65% to 75% of patients with advanced breast or prostate cancer have bone metastases, which can lead to devastating complications...
Web Exclusives published on November 30, 2018 in FDA Approvals, News & Updates
On June 27, 2018, the FDA approved the combination of encorafenib and binimetinib (Braftovi and Mektovi; Array BioPharma), 2 new kinase inhibitors, for the treatment of patients with unresectable or metastatic melanoma and the BRAF V600E or BRAF V600K mutation, as detected by the companion diagnostic THxID BRAF Kit, which was approved on the same day.
Web Exclusives published on November 30, 2018
As more patients with cancer use cannabis to treat symptoms and for the cancer itself, oncologists need to understand these medicines’ potential benefits and side effects, explains Declan Walsh, MD, MSc.
Web Exclusives published on November 26, 2018 in Immunotherapy
Learning how to activate and harness the immune system—the body’s built-in defense against disease—has brought the field of oncology to the cusp of a cure for at least some, if not many, types of cancer, according to an international authority in immuno-oncology.
Web Exclusives published on November 26, 2018 in Drug Therapies
New cancer therapies have significantly improved survival outcomes, but have brought with them a wide range of oral toxicities, many of which are class-specific and otherwise new to the field of oncology, according to Nathaniel S. Treister, DMD, DMSc, Division Chief, Division of Oral Medicine and Dentistry, Brigham and Women’s Hospital, Boston, MA.
Web Exclusives published on November 20, 2018 in Emerging Therapies
Chicago, IL—A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a pre­liminary phase 1b clinical trial. The addition of CMP-001 to pembrolizu­mab was well-tolerated, with encouraging antitumor responses in patients with metastatic melanoma that progressed with or after treatment with a PD-1 inhibitor.
Web Exclusives published on November 13, 2018 in FDA Approvals, News & Updates
In August, the FDA approved lenvatinib for the first-line treatment of patients with unresectable hepatocellular carcinoma, based on the results of the REFLECT clinical trial.
Web Exclusives published on November 13, 2018 in Immunotherapy
“This study is a fantastic advance for patients with brain metastases. It shows that combination immunotherapy can shrink brain metastases in a substantial proportion of patients,” said Michael A. Postow, MD.
Web Exclusives published on October 22, 2018 in Immunotherapy
“The overall survival findings are far superior to what we might anticipate with traditional therapies in this relapsed or refractory DLBCL population,” said Jeremy S. Abramson, MD, MMSc.
Web Exclusives published on October 22, 2018 in Breast Cancer
Analysis of a phase 3 clinical trial showed that 6 months of trastuzumab was noninferior to 12 months in terms of disease-free survival, and was also associated with a 50% reduction in cardiotoxicity.
Page 3 of 12
Results 21 - 30 of 115